From Lexaria Facebook Group Moderator Today's Update;


· 14h ·
NEAR TERM CATALYSTS
2021 STUDY PROGRAM HIGHLIGHTS
NASDAQ:LEXX | NASDAQ:LEXXW | CSE:LXX
2021 Hypertension Program: 5 Studies
3 Human and 2 Animal Studies utilizing CBD to regulate
blood pressure and blood flow.
HYPER-A21-1 Successful results from first Animal Study.
HYPER-A21-2 Animal results are due in June.
HYPER-H21-1 (24-person) Human clinical 300mg PK study;
final results due in September.
HYPER-H21-2 (16-person) Human clinical 150mg x 3 doses
PK and sleep study; final results due in November.
HYPER-H21-3 (16-person) Human clinical 300mg Hypoxic
Pulmonary Vasoconstriction study; final results due in
December.
2021 Antiviral Program: 4 Studies
1 Live-cell and 3 Animal Studies utilizing Remdesivir and other
antiviral drugs studying PK and efficacy.
VIRAL-A20-2 Animal results are due in May.
VIRAL-C21-3 Live-cell study will test whether DehydraTECHprocessed antiviral drugs including Remdesivir are able to kill
SARS-CoV-2 live virus. Results due in June.
VIRAL-A20-3 Animal results are due in June.
VIRAL-MC21-1 Results are due in August.